



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/00, C07K 14/295</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/46359</b> <b>(43) International Publication Date:</b> 10 August 2000 (10.08.00)
<b>(21) International Application Number:</b> PCT/GB00/00237 <b>(22) International Filing Date:</b> 28 January 2000 (28.01.00)  <b>(30) Priority Data:</b> 9902555.3                      5 February 1999 (05.02.99)                      GB  <b>(71) Applicant (for all designated States except US):</b> NEUTEC PHARMA PLC [GB/GB]; St. James's Court, Brown Street, Manchester, Cheshire M2 2JF (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BURNIE, James, Peter [GB/GB]; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY (GB). MATTHEWS, Ruth, Christine [GB/GB]; 1 Greystoke Drive, Alderley Edge, Cheshire SK9 7PY (GB).  <b>(74) Agent:</b> MCNEIGHT & LAWRENCE; Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> MEDICAMENT		
<b>(57) Abstract</b>		
<p>The present invention concerns treatment, prevention and diagnosis of infection due to <i>Chlamydia pneumoniae</i> and in particular to the prevention and treatment of atherosclerosis, including coronary atherosclerosis, caused by same.</p>		

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### Medicament

The present invention concerns treatment, prevention and diagnosis of infection due to *Chlamydia pneumoniae* and in particular to the prevention and treatment of atherosclerosis, including coronary atherosclerosis, caused by same.

*C. pneumoniae* is associated with atherosclerosis but no definitive link between the two has yet been established (Hammerschlag, M.R., 1998, Eur. J. Clin. Microbiol. Infect. Dis., 17: 305-308). Friedank, H.M. *et al.* (1993, Eur. J. Clin. Microbiol. Infect. Dis., 12(12): 947-951) identify a 54 kDa *C. pneumoniae* antigen which was recognised by 93% of sera positive for *C. pneumoniae*, the antigen appearing to be located on the surface of elementary bodies. Wiedman, A.A.M. *et al.* (1997, Clin. Diagn. Labs. Immunol., 4(6):700-704) showed the infectivity of *C. pneumoniae* elementary bodies to be slightly reduced by the use of antibody specific against a 54 kDa *C. pneumoniae* protein.

Despite investigating it, other researchers have not confirmed the immunogenicity of the *C. pneumoniae* 54 kDa band (see for example Kutlin, A. and Roblin, P.M., 1998, J. Infect. Dis., 177: 720-724; Campbell, L.A. *et al.*, 1990, J. Clin. Microbiol., 28(6): 1261-1264; Campbell, L.A. *et al.*, 1990. Infection and Immunity, 58(1): 93-97; Puolakkainen, M. *et al.*, 1993, J. Clin. Microbiol., 31(8): 2212-2214; hkima, Y. *et al.*, 1994, J. Clin. Microbiol., 32(3): 583-588; Maass, M. and Gieffers, J., 1997, J. Infection, 35: 171-176; Gonen, R. *et al.*, 1993, APMIS, 101:719-726).

The present inventor has now succeeded in isolating, purifying and identifying a *C. pneumoniae* protein which (together with inhibitors of same, such as

antibodies) is protective and therapeutic against *C. pneumoniae* infection. The therapeutic role of the protein has previously neither been suggested nor disclosed.

According to the present invention there is provided a *C. pneumoniae* protein having the amino acid sequence of SEQ ID NO: 2, for use in a method of treatment or diagnosis of the human or animal body. The amino acid sequence has been confirmed by N-terminal amino-acid sequencing (see "Experimental" below) and the protein has a theoretical molecular weight of 50.8 kDa, although post-translational modifications such as glycosylation may of course affect its apparent molecular weight as determined by e.g. SDS-PAGE. Experiments (below) have shown it to have an apparent molecular weight of 51 kDa on SDS-PAGE gels.

As can be seen from the plethora of publications above, although some identify immunogenic bands at molecular weights of 50-54 kDa, no specific therapeutically effective proteins have been identified.

Experiments (below) have allowed the present inventor to isolate and purify the protein of the present invention and identify the gene sequence coding for the protein. This has allowed the determination of the protein amino acid sequence (above). The nucleotide sequence coding for same forms another part of the present invention. Thus according to the present invention there is also provided a nucleotide sequence coding for a protein according to the present invention, for use in a method of treatment or diagnosis of the human or animal body. Such a nucleotide sequence may have the sequence of SEQ ID NO: 1. Modified nucleotide sequences having codons encoding the same amino acid sequence will be readily apparent to one skilled in the art.

The nucleotide sequence of the present invention and the amino acid sequence it encodes are already known from the Chlamydia Genome Project

(*C. pneumoniae* CWL029/CPn0809), as is an apparent *C. trachomatis* homologue (CT578). However, therapeutic and diagnostic uses for same have not been previously suggested.

The invention also extends to encompass forms of the protein which have been insubstantially modified (i.e. which have been partially modified), particularly forms of the protein which display the same immunogenic properties as the protein itself.

By "partial modification" and "partially modified" is meant, with reference to amino acid sequences, a partially modified form of the molecule which retains substantially the properties of the molecule from which it is derived, although it may of course have additional functionality. Partial modification may, for example, be by way of addition, deletion or substitution of amino acid residues. Substitutions may be conserved substitutions. Hence the partially modified molecule may be a homologue of the molecules from which it was derived. It may, for example, have at least 70% homology with the molecule from which it was derived. It may for example have at least 80, 90 or 95% homology with the molecule from which it was derived. An example of a homologue is an allelic mutant.

Also provided according to the present invention is the use of a protein, immunogenic fragment thereof or nucleic acid sequence encoding same according to the present invention in the manufacture of a medicament for the treatment of infection due to *C. pneumoniae*.

Immunogenic fragments of the protein include any fragment of the protein which elicits an immune response, and includes epitopes. Analogues (mimotopes) of epitopes may be readily created, the mimotopes having different sequences but displaying the same epitope and thus the term "immunogenic fragments" also

encompasses immunogenic analogues of the fragments e.g. mimotopes. Epitopes may be readily determined and mimotopes readily designed (Geysen, H.M. *et al.*, 1987, *Journal of Immunological Methods*, 102: 259-274; Geysen, H.M. *et al.*, 1988, *J. Mol. Recognit.*, 1(1):32-41; Jung, G. and Beck-Sickinger, A.G., 1992, *Angew. Chem. Int. Ed. Eng.*, 31: 367-486). Such an immunogenic fragment carrying epitopes may also be described as being a peptide having the amino acid sequence of the immunogenic fragment and which carries an epitope.

The present inventor has succeeded in isolating a number of epitopes (immunogenic fragments) of the protein of the present invention. Thus according to the present invention there is also provided an epitope having the amino acid sequence of any one of SEQ ID NOs: 4-14. In particular, SEQ ID NOs: 5-7 provide an overlapping set of highly immunogenic peptides - as can be seen from the experimental data (below) SEQ ID NO: 5 provides for especially good results. Similarly, excellent results are also obtained from SEQ ID NO: 8.

The protein, immunogenic fragments thereof and nucleic acid sequences encoding same may be used in therapy, both prophylactically (e.g. as immunostimulants such as vaccines) and for treatment of infection due to *C. pneumoniae*. For example a nucleotide sequence encoding the protein or immunogenic fragment thereof may be used in the manufacture of a DNA vaccine (Montgomery, D.L. *et al.*, 1997, *Pharmacol. Ther.*, 74(2): 195-205; Donnelly, J.J. *et al.*, 1997, *Annu. Rev. Immunol.*, 15: 617-648; Manickan, E. *et al.*, 1997, *Crit. Rev. Immunol.*, 17(2): 139-154).

Binding agents and inhibitors (such as antibodies or other neutralising agents) specific against the protein and immunogenic fragments thereof may also be used both diagnostically and therapeutically. Binding agents have a target to which they are specific, and in the case of a binding agent being an antibody, the target is an antigen.

An example of a therapeutic medicament is antibody specific against the protein of the present invention, and this may be employed in immunotherapy, for example passive immunotherapy. Antibodies, their manufacture and use are well known (Harlow, E. and Lane, D., "Using Antibodies - A Laboratory Manual", Cold Spring Harbor Laboratory Press, New York, 1998) and so antibodies and antigen binding fragments thereof will be readily apparent to one skilled in the art, and reference herein to antibodies is also reference to antigen binding fragments unless stated otherwise. Other inhibitors such as ribozymes, antisense oligonucleotides and DNA vaccines will be readily apparent to one skilled in the art (Fries, P.C., 1999, "DNA Vaccines", New England Journal of medicine, 341: 1623-1624; Leitner, W.W. *et al.*, 1999, "DNA and RNA based vaccines: principles, progress and prospects", Vaccine, 18: 765-777; Muotri, A.R. *et al.*, 1999, "Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function", Gene, 237: 303-310; Rossi, J.J., 1999, "Ribozymes, genomics and therapeutics", Chemistry & Biology, 6: R33-R37; James, H.A., 1999, "The potential application of ribozymes for the treatment of haematological disorders", Journal of Leukocyte Biolofy, 66: 361-368)

Thus the present invention also provides the use of a inhibitor specific to the protein of the present invention in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.

Also provided according to the present invention is a method of manufacture of a medicament for the treatment of infection due to *C. pneumoniae*, characterised in the use of a protein, immunogenic fragment or inhibitor according to the present invention.

Also provided according to the present invention is a method of treatment of infection due to *C. pneumoniae*(e.g. of a patient in need of same), comprising the step

of administering to a patient a medicament comprising a protein, immunogenic fragment or inhibitor according to the present invention. The exact dose of medicament administered to a patient may be readily determined using simple dose-response assays. Medicaments may additionally comprise a pharmaceutically acceptable carrier, diluent or excipient (Remington's Pharmaceutical Sciences and US Pharmacopeia, 1984, Mack Publishing Company, Easton, PA, USA)

It has not been previously suggested that the protein of the present invention (or immunogenic fragments of same) is diagnostic for infection due to *C. pneumonia*. Binding agents specific to the protein of the present invention (for example antibodies) may also be used diagnostically, for example in an ELISA-type test. Thus also provided according to the present invention is the use of a protein, immunogenic fragment or binding agent according to the present invention in the manufacture of a diagnostic test for *C. pneumoniae*.

Also provided is a diagnostic test method for infection due to *C. pneumoniae* comprising the steps of:

- I) reacting an antibody specific against the protein of the present invention with serum from a patient;
- ii) detecting an antibody-antigen binding reaction; and
- iii) correlating the detection of an antibody-antigen binding reaction with the presence of the protein.

Such test methods may also be performed using other binding agents specific to the protein of the present invention.

Also provided is a kit of parts for performing such a test, characterised in that it comprises antibody specific against the protein of the present invention.



The invention will be further apparent from the following description, with reference to the several figures of the accompanying drawings, which show, by way of example only, uses of the proteins of the present invention.

## EXPERIMENTAL

The experiments below detail the identification of a number of peptides and antisera against same which are useful in the therapy and diagnosis of infections due to *Chlamydia pneumoniae*. Starting with sera from infected patients, blotting against clinical isolates of *Chlamydia pneumoniae* showed the presence of an immunodominant antigen with an apparent molecular weight of 51 kDa, the antigen being stable to and released by octylglucoside treatment. N-terminal amino acid sequencing of the protein of the 51 kDa band allowed sequence database probing, in turn identifying a *C. pneumoniae* protein and a *C. trachomatis* homologue. Epitope mapping allowed the identification of antigenic peptides, which together with antibody against them were tested for their therapeutic and diagnostic efficacy.

Western Blotting - Using the Novex nuPAGE Electrophoresis System.

### 1. SDS PAGE

#### *Preparation of Sample:*

1. 100 µl of Novex SDS Sample loading buffer was added to 400 µl of a preparation of a *Chlamydia pneumoniae* clinical isolate and the mixture placed into a boiling waterbath for 10 minutes.
2. 10 µl of the mixture was loaded into each well of a Novex 4-12% Bis-Tris NuPage gel (1.0 mm, 12 well). In addition, 4 µl of Novex Multimark molecular weight standards were added to a single well on each gel.
3. Electrophoresis was performed using 1x Novex MOPS electrophoresis buffer at 200v for 40 minutes.

*Western Transfer Protocol:*

1. The blotting apparatus and the gel membrane “sandwiches” were assembled according to the protocol described in the Novex instruction booklet provided with the gels.
2. Blotting was performed using 1x Novex Transfer buffer containing 20% methanol. Transfer was carried out at 30v (constant) for 1 hour.
3. Following transfer, the membranes were removed from the apparatus and left to “Block” overnight in 3% Bovine Serum Albumin (BSA) at 4 °C.

*Probing With Patient's Serum:*

1. The membranes were cut into strips and placed into the wells of incubation trays. Patients' serum was diluted 1 in 20 in 3% BSA and 2 ml added to each strip. (2 strips per patient).
2. The membranes were incubated at room temperature for 2 hours with agitation.
3. The strips were washed 5 times over 30 minutes with 0.85% NaCl/0.01% Tween 20.
4. 2 ml of goat anti-human IgM or IgG alkaline phosphatase conjugated anti-immunoglobulin diluted 1 in 4000 in 3% BSA were added to each strip. The strips were incubated for a further hour at room temperature with agitation.
5. The membranes were washed a further 5 times as previously described.

6. Antibody-antigen interaction was visualised by the addition of NBT/BCIP (50 mg/ml) in pH 9.5 phosphate buffer.
7. The reaction was allowed to proceed until the bands had reached the required intensity.

### Sera

- Group A: Children with respiratory tract infection and no evidence of *Chlamydia pneumoniae* as shown by negative microimmunofluorescence (less than 1 in 64) test (n=19).
- Group B: Children with respiratory tract infection and a microimmunofluorescence titre greater than 1 in 512 (n=18).
- Group C: Patients undergoing cardiac surgery for advanced coronary disease (n=32). Ten of these had antibody on immunoblot.
- Group D: Adults with respiratory tract infection and a chlamydia complement fixation test greater than 1 in 40 (n=27) using LGV 2 as an antigen.
- Group E: Adults with pelvic inflammatory disease due to *Chlamydia trachomatis* (n=21).
- Group F: Sera (n=11) which were positive for the 60/62 kDa doublet and band at 51 kDa were retested on antigen prepared from *Chlamydia pneumoniae* where the purified elementary bodies were incubated with 1% octylglucoside at 37 °C for 30 minutes rather than in SDS.

**Results:**

Results of the sera blotting experiments are shown in Table 1. It should be noted that sera blotting determines the presence in patients of antibodies specific against a given antigen, and so when a patient has previously been infected by a pathogen and developed an immune response against an antigen, that immune response may still be detectable at a later date when the patient is no longer infected. Hence background results must be interpreted in light of the general infection of a population by the pathogen. For example, the general population has an infection rate by adulthood of approximately 10% for *C. pneumoniae*, thus a background rate of detection of *C. pneumoniae* antigens of up to 10% should be expected.

**Conclusions:**

The sera from Group A children did not recognise *C.pneumoniae* on immunoblot. The Group B sera from children with evidence of *C.pneumoniae* infection recognised a range of antigens with apparent molecular weights ranging from 30 to 180 kDa. IgM for an antigen complex at 60/62 kDa which occurred as a doublet was immunodominant as well as an antigen at 51 kDa. For IgG the antibody was most pronounced for the antigen at 51 kDa. In the cardiac patients, 23 produced antibody and this was for IgM against the bands at 67, 60/62 and 51 kDa. For IgG this was the band at 51 kDa. For Group D IgM was most pronounced for the 60/62 kDa doublet and IgG for the band at 180 kDa and the doublet at 60/62 kDa. This group of sera contains those with infection most likely due to *Chlamydia psittaci*. The sera from Group E patients infected with *Chlamydia trachomatis* did not cross-react.

**Group F Sera**

On re-blotting with those sera previously positive for the 60/62 kDa doublet and 51 kDa, the doublet disappeared whilst the band at 51 kDa remained. This showed that the band at 51 kDa was stable to and released by octylglucoside treatment.

### **Solubility in Octylglucoside**

Using samples from Group F patients, separation of antigens from elementary bodies using 1-D gel electrophoresis and SDS gave a different staining pattern compared to using 1-D gel electrophoresis and octylglucoside. The 51 kDa band was still visible after octylglucoside. The pair of antigenic bands at 60/62 kDa was not visible in octylglucoside. Therefore a distinguishing character of the 51 kDa antigen of the present invention is its solubility in octylglucoside.

### **N-Terminal Amino Acid Sequencing**

N-Terminal amino-acid sequencing was performed upon the 51 kDa band. The resulting sequence was then used to query the Chlamydia Genome Project database which identified the protein of SEQ ID NO: 2 and a *C. trachomatis* homologue.

### **Epitope Mapping**

A series of overlapping peptides of 15 amino acids covering the derived amino acid sequence of the protein were synthesised on polyethylene pins with reagents from an epitope scanning kit (Cambridge Research Biochemicals, Cambridge, UK) as described previously by Geysen *et al.* (1987, Journal of Immunological Methods, 102: 259-274). Peptide 1 consisted of residues 1 to 15, peptide 2 consisted of residues 2 to 16 etc. The reactivity of each peptide with patient sera (diluted 1:200) was determined for IgG by ELISA. Data were expressed as A405 after 30 minutes of incubation.

Sera from patients as follows:

- Group 1: Children with respiratory tract infection and no evidence of *Chlamydia pneumoniae* as shown by negative immunoblot and microimmunofluorescence (less than 1 in 64) (n = 3).
- Group 2: Children with respiratory tract infection, positive immunoblot and microimmunofluorescence test greater than 1 in 512 (n = 6).
- Group 3: Patients undergoing cardiac surgery for advanced coronary disease and antibody on immunoblot (n = 2).
- Group 4: Patients presenting with history of chest pain, negative troponin (<0.2), negative immunoblot (n = 3).
- Group 5: Patients presenting with early coronary, positive troponin (>0.2) and antibody on immunoblot (n = 8).

## Results

### *Epitope mapping*

Epitope mapping defined eleven areas where children with acute chlamydial infection produced wells with a mean optical density (OD) greater than 1. In the case of epitopes having SEQ ID NOs: 4, 5, 6, 7, 8, 10, 12 and 14 the mean OD was at least 2 standard deviations above that of Group 1 (children with no evidence of *C.pneumoniae* infections). This applied also to Groups 3, 4 and 5 with the exception of SEQ ID NO: 5 which was positive in Groups 4 and 5.

Peptide 1 (SEQ ID NO: 15) representing epitope having the sequence of (i.e. which is carried by the peptides having the sequence of) SEQ ID NO: 8 and peptide 2 (SEQ ID NO: 16) representing the carboxy end of SEQ ID NO: 4, the epitope having the sequence of SEQ ID NO: 5 and the amino end of SEQ ID NO: 6 were synthesised.

### Preparation of rabbit polyclonal serum

New Zealand white rabbits were pre-bled and then immunised subcutaneously with either peptide 1 or peptide 2 (0.1 ml of 1 mg/ml) conjugated to KLH suspended in either Freund's adjuvant (injection at day 0) or Freund's incomplete adjuvant on days 14, 42, and 70). Serum was obtained for indirect ELISA at the terminal bleed-out.

#### Indirect ELISA

By a simple adsorption of each peptide to a microtitre plate the following procedure was performed. The peptide was dissolved in 2 ml of 0.01 M phosphate buffer saline (PBS), pH 7.2 and diluted to a concentration of 10 µg/ml (1/100) in the same buffer.

1. 150 µl aliquots of peptide (10 µg/ml in 0.01 M PBS) were pipetted into the wells of a Falcon 3912 microassay plate and were incubated overnight at 4 °C.
2. The unbound peptide was removed by washing four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS (pH 7.2).
3. The plates were blocked with 2% skimmed milk-10% FCS in 0.01 M PBS for 1 hour at 37 °C.
4. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS and the serum under investigation was added (1/100 dilution in blocking solution) into the wells of micro assay plate (three wells used for each serum) and incubated for 2 hours at 37 °C.
5. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS and secondary antibody, anti-rabbit IgG peroxidase conjugate (1/1000 dilution in blocking solution) was added and incubation proceeded for 1 hour at 37 °C.
6. The plates were washed four times (4 x 10 minutes) with 0.05% Tween 20 in 0.01 M PBS, followed by a further washing with 0.01 M PBS. The plate was then incubated for 45 minutes at room temperature with agitation in 0.5



mg/ml of freshly prepared 2,2 Azino-bis [3-ethylbenz-thiazoline-6-sulfonic acid] diammonium (ABTS tablets) in pH 4.0 citrate buffer with 0.01% (w/v) hydrogen peroxide.

7. Optical density (OD) measurements were made with an ELISA plate reader (Titertek Miltiscan) at a wavelength of 405 nm.
8. The average readings for each three wells for each serum was determined.

### Results

The results shown in Table 3 demonstrate seroconversion to each individual peptide.

### Expression of the amino-end of the protein

The sequence was codon optimised (Genosys, California) for *E.coli* and a BamHI and NotI site added to opposite ends. The optimised sequence and PET 29 vector (Novagen, Wisconsin) were restriction digested using BamHI and NotI and transformed by heat shock into *E.coli* strain BL21 (Invitrogen, Carlsbad, California). The expressed amino acids were from amino acids 1-292 and included the epitopes represented by peptides 1 and 2. This construct included an S-tag and Thrombin cleavage site at the amino end and histidine tag at the carboxy end (SEQ ID NO: 3).

### Purification

The transformants were expressed as follows. Briefly, 5 ml of an overnight culture was used to inoculate 500 ml LB (50 µg/ml kanamycin, 34 µg/ml chloramphenicol) which was grown for 2 hours at 37 °C to an OD 600 of 0.5, then induced for 3 hours with 0.1 mM IPTG (Sigma, Poole Dorset). The cells were pelleted and disrupted by crushing at -20 °C in an XPRESS. The buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.5 M NaCl, 10 mM imidazole) and the cell debris pelleted down. The supernatant was filter sterilised and put on a Ni-NTA agarose slurry affinity column (Qiagen) in order to capture the His-tagged recombinant protein. The column was washed 3 times with 4 ml of washing buffer and

the protein eluted maximally with 150 mM imidazole. The protein gave a single band on a 10% acrylamide gel stained with Coomassie Brilliant Blue with an apparent molecular weight of 37 kDa. On Western blot counterstaining with the anti-His mouse alkaline phosphate conjugate (1:2,500) (Sigma, Dorset, Poole) this produced a single band at 37 kDa and a breakdown product at 35 kDa. The protein concentration of the elute was measured and standardised to 10 mg/ml.

#### Amino acid sequencing

The protein was amino end cleared to remove the S-tag using a Thrombin cleavage Kit (Novagen). The digestion reaction was 5 µl 10 x Thrombin cleavage buffer, 0.5 mg purified recombinant protein, 1 µl of 0.01 µg/ml Thrombin which was left at room temperature for 18 hours. The reaction mix was run on a 12% SDS-PAGE gel and transferred onto PVDF membrane (Amersham, Chalfont, UK). This was stained with Coomassie Brilliant Blue and the protein bands destained and excised. Direct amino acid sequencing gave amino acids 28-32 of SEQ ID NO: 3 which matched the amino end (Department of Biochemistry, University of Cambridge).

#### Human recombinant antibodies

These peptides and the purified recombinant proteins were used to pan the phage display library. The peptide and recombinant protein were used at 10 mg/ml on NunC immunotubes Bst-N1 fingerprints of the PCR-amplified ScFv inserts before panning showed a highly heterogeneous library. After panning against peptide 1, 7 fingerprints were identified of which four were represented by more than one clone (A, B, C, D). These were combined as a pool for a neutralisation assay (pool 1) (below). After panning against peptide 2, clone A was present as well as a new ScFv, E. A and E were combined to produce pool 2. Against the clone recombinant fragment ScFvs E, F and G were present as well as a further ScFv, H. ScFvs E, F, G and H were tested together as pool 3.

### Neutralisation assays

Chang cells (50 ml of  $10^6$  cells/ml) in maintenance media were grown overnight at 37 °C with 5% CO<sub>2</sub>. Chang cells (1 ml of  $1 \times 10^6$  cells/ml maintenance media) were grown overnight at 37 °C with 5% CO<sub>2</sub> in plastic bijoux containing a thin glass circle on which the cells can grow. For recombinant protein or peptide assay (0.1 µl/ml), 100 µl of each sample was incubated with shaking for 1 hour with the cells at 37 °C. For the phage and sera assays, 100 µl of each sample (1:10 rabbit sera or dialysed phage pools 1-3) were incubated with 100 µl elementary bodies (EB) for 1 hour at 37 °C, shaking. After this first incubation, the 100 µl EB or 200 µl of the phage or rabbit sera/EB mix was added to the Chang cells. This was incubated with shaking for 1 hour at 37 °C. The supernatant was removed from every sample and replaced by 1 ml of fresh maintenance media. This was incubated at 37 °C with 5% CO<sub>2</sub> for 72 hours.

For both assays, the inclusion bodies were fixed and stained the following way; the cells were washed twice with PBS, then fixed with 100% methylated spirits for 10 minutes and washed twice again with PBS. The glass circles were incubated for 30 minutes with 10 µl of mouse *C.pneumoniae* inclusion bodies monoclonals (Mab) then washed 3 times with PBS and incubated for 30 minutes with 100 µl of fluorescein conjugated anti-mouse IgG. The inclusion bodies were then observed by fluorescence microscopy and three 200X fields counted. EB only samples were used as a positive control for chlamydial infection and dialysed phage supernatant without EB as a negative control.

### Results

See Table 4 (Table of Neutralisation Assays).

### Conclusion

Pre-incubation with the rabbit antiserum against peptide 2 and peptide 2 itself reduced the infectivity due to *C.pneumoniae*. Incubation with peptide 1 produced a similar reduction . The pools of phages were also active.

Overall this demonstrated the immunogenicity of the antigen, the potential therapeutic effect of peptides representing its key epitopes and both rabbit hyperimmune antiserum and ScFvs against these epitopes.

Table 1

Apparent Molecular Weight (kDa)	Group B (N=18)		Group C (N=18)		Group D (N=27)		Group E (N=21)	
	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG
180	1	2		2	1	6		1
130		2			1	4		
120	1	5		1	1	5		1
98		5		1	2	5		2
90		2				2		
67		2	5	1			1	1
60/62*	8	5	5		13	7	2	2
51	7	11	9	10	2	3	1	2
47	1	1	1		0	0	0	0
40	0	0	0	3	0	0	0	1
30		4	0	3		2		2

\* runs as a doublet within 1 mm of each other

Table 2

Well No.	Epitope SEQ ID NO	Value for <sup>a</sup>				
		Group 1 (n = 3)	Group 2 (n = 6)	Group 3 (n = 2)	Group 4 (n = 3)	Group 5 (n = 8)
3	9	0.538±0.205	1.028±0.423	0.425±0.036	0.416±0.184	0.499±0.191
4		0.599±0.252	1.487±0.462	0.502±0.036	0.407±0.107	0.438±0.162
13	10	0.462±0.203	1.103±0.229	0.473±0.026	0.421±0.162	0.427±0.188
31	11	0.491±0.192	1.103±0.310	0.440±0.004	0.407±0.105	0.310±0.129
41	12	0.547±0.235	1.169±0.256	0.474±0.024	0.393±0.08	0.376±0.158
43	13	0.598±0.258	1.223±0.323	0.558±0.015	0.423±0.119	0.406±0.181
55	4	0.547±0.235	1.265±0.334	0.475±0.02	0.373±0.076	0.381±0.042
58	5	0.611±0.019	1.025±0.06	0.611±0.019	1.127±0.253	0.800±1.232
59	6	0.494±0.166	1.096±0.267	0.547±0.009	0.546±0.200	0.702±0.144
60	7	0.489±0.129	1.048±0.270	0.483±0.064	0.388±0.008	0.449±0.140
61		0.530±0.236	1.051±0.262	0.59±0.089	0.446±0.09	0.784±0.257
76	8	0.485±0.158	1.174±0.255	0.654±0.068	0.564±0.223	0.666±0.266
79	14	0.510±0.235	1.21±0.273	0.418±0.003	0.423±0.127	0.388±0.153

<sup>a</sup> Optical density ± Standard deviation

Table 3

	<sup>a</sup> Pre Serum	Post Serum
Peptide 1	0.055 ± 0.01	0.591 ± 0.06
Peptide 2	0.056 ± 0.01	0.507 ± 0.04

<sup>a</sup> optical density ± standard derivation

Table 4 - Table of Neutralisation Assays

	Number of Elementary Bodies in Three 200x Fields
Cell control (dialysed phage supernatant)	0
Cell control (elementary bodies)	30
<u>Rabbit anti-serum</u>	
Versus peptide 1	30
Versus peptide 2	19
<u>Pre-incubation</u>	
Peptide 1	13
Peptide 2	0
Recombinant protein	12
<u>Phage Pools</u>	
Pool 1	18
Pool 2	N/D
Pool 3	21

### CLAIMS

1. A *C.pneumoniae* protein having the amino acid sequence of SEQ ID NO: 2 for use in a method of treatment or diagnosis of the human or animal body.
2. A nucleotide sequence encoding a protein according to claim 1 for use in a method of treatment of the human or animal body.
3. A nucleotide sequence according to claim 2, having the sequence of SEQ ID NO: 1.
4. The use of a protein, immunogenic fragment thereof or nucleotide sequence encoding same according to any one of the preceding claims in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
5. The use of an immunogenic fragment according to claim 4, having the amino acid sequence of any one of SEQ ID NOs: 4-14 in the manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
6. The use of an inhibitor specific against the protein, immunogenic fragment or nucleotide sequence encoding same according to any one of the preceding claims in a method of manufacture of a medicament for the treatment of infection due to *C.pneumoniae*.
7. The use of an inhibitor according to claim 6, the inhibitor being selected from the group of an antibody, DNA vaccine, ribozyme and antisense oligonucleotide.



8. A method of manufacture of a medicament for the treatment of infection by *C.pneumoniae* characterised in the use of a protein, immunogenic fragment thereof or nucleotide sequence encoding same according to either one of claims 4 or 5.
9. A method of manufacture of a medicament for the treatment of infection due to *C.pneumoniae* characterised in the use of an inhibitor according to either one of claims 6 or 7.
10. The use of a protein according to claim 1 or an immunogenic fragment thereof or a binding agent specific to same or an inhibitor of same in the manufacture of a diagnostic test for *C.pneumoniae*.
11. A kit of parts for a diagnostic test for *C.pneumoniae*, characterised in that it comprises a protein according to claim 1 or an immunogenic fragment thereof or a binding agent specific to same or an inhibitor of same.
12. A diagnostic test method for infection due to *C.pneumoniae* comprising the steps of:
  - i) reacting an antibody specific against the protein according to claim 1 with serum from a patient;
  - ii) detecting an antibody - antigen binding reaction; and
  - iii) correlating the detection of an antibody - antigen binding reaction with the presence of the protein.

13. A diagnostic test method according to claim 12, being a method of diagnosis of the human or animal body.

14. A method of treatment of infection due to *C.pneumoniae* comprising the step of administering to a patient a medicament comprising a protein, immunogenic fragment thereof, nucleotide sequence encoding same or an inhibitor thereof according to any one of claims 4-7.

- 1 -

## SEQUENCE LISTING

&lt;110&gt; NeuTec Pharma plc

&lt;120&gt; Medicament

&lt;130&gt; M99/0035/PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; GB9902555.3

&lt;151&gt; 1999-02-05

&lt;160&gt; 16

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1491

&lt;212&gt; DNA

&lt;213&gt; Chlamydia pneumoniae

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(1491)

&lt;400&gt; 1

gat aca aac atg tct att tca tct tct tca gga cct gac aat caa aaa	48
Asp Thr Asn Met Ser Ile Ser Ser Ser Ser Gly Pro Asp Asn Gln Lys	
1 5 10 15	
aat atc atg tct caa gtt ctg aca tcg aca ccc cag ggc gtg ccc caa	96
Asn Ile Met Ser Gln Val Leu Thr Ser Thr Pro Gln Gly Val Pro Gln	
20 25 30	
caa gat aag ctg tct ggc aac gaa acg aag caa ata cag caa aca cgt	144
Gln Asp Lys Leu Ser Gly Asn Glu Thr Lys Gln Ile Gln Gln Thr Arg	
35 40 45	
cag ggt aaa aac act gag atg gaa agc gat gcc act att gct ggt gct	192
Gln Gly Lys Asn Thr Glu Met Glu Ser Asp Ala Thr Ile Ala Gly Ala	
50 55 60	
tct gga aaa gac aaa act tcc tcg act aca aaa aca gaa aca gct cca	240
Ser Gly Lys Asp Lys Thr Ser Ser Thr Thr Lys Thr Glu Thr Ala Pro	
65 70 75 80	
caa cag gga gtt gct gct ggg aaa gaa tcc tca gaa agt caa aag gca	288
Gln Gln Gly Val Ala Ala Gly Lys Glu Ser Ser Glu Ser Gln Lys Ala	
85 90 95	
ggt gct gat act gga gta tca gga gcg gct gct act aca gca tca aat	336

- 2 -

Gly	Ala	Asp	Thr	Gly	Val	Ser	Gly	Ala	Ala	Ala	Thr	Thr	Ala	Ser	Asn		
			100					105					110				
act	gca	aca	aaa	att	gct	atg	cag	acc	tct	att	gaa	gag	gcg	agc	aaa	384	
Thr	Ala	Thr	Lys	Ile	Ala	Met	Gln	Thr	Ser	Ile	Glu	Glu	Ala	Ser	Lys		
			115				120					125					
agt	atg	gag	tct	acc	tta	gag	tca	ctt	caa	agc	ctc	agt	gcc	gcg	caa	432	
Ser	Met	Glu	Ser	Thr	Leu	Glu	Ser	Leu	Gln	Ser	Leu	Ser	Ala	Ala	Gln		
			130				135					140					
atg	aaa	gaa	gtc	gaa	gcg	gtt	gtt	gtt	gct	gcc	ctc	tca	ggg	aaa	agt	480	
Met	Lys	Glu	Val	Glu	Ala	Val	Val	Val	Ala	Ala	Leu	Ser	Gly	Lys	Ser		
					150				155						160		
tcg	ggc	tcc	gca	aaa	ttg	gaa	aca	cct	gag	ctc	ccc	aag	ccc	ggg	gtg	528	
Ser	Gly	Ser	Ala	Lys	Leu	Glu	Thr	Pro	Glu	Leu	Pro	Lys	Pro	Gly	Val		
				165					170					175			
aca	cca	aga	tca	gag	gtt	atc	gaa	atc	gga	ctc	gcg	ctt	gct	aaa	gca	576	
Thr	Pro	Arg	Ser	Glu	Val	Ile	Glu	Ile	Gly	Leu	Ala	Leu	Ala	Lys	Ala		
				180				185						190			
att	cag	aca	ttg	gga	gaa	gcc	aca	aaa	tct	gcc	tta	tct	aac	tat	gca	624	
Ile	Gln	Thr	Leu	Gly	Glu	Ala	Thr	Lys	Ser	Ala	Leu	Ser	Asn	Tyr	Ala		
			195				200						205				
agt	aca	caa	gca	caa	gca	gac	caa	aca	aat	aaa	cta	ggc	cta	gaa	aag	672	
Ser	Thr	Gln	Ala	Gln	Ala	Asp	Gln	Thr	Asn	Lys	Leu	Gly	Leu	Glu	Lys		
			210				215					220					
caa	gcg	ata	aaa	atc	gat	aaa	gaa	cga	gaa	gaa	tac	caa	gag	atg	aag	720	
Gln	Ala	Ile	Lys	Ile	Asp	Lys	Glu	Arg	Glu	Glu	Tyr	Gln	Glu	Met	Lys		
			225			230				235					240		
gct	gcc	gaa	cag	aag	tct	aaa	gat	ctc	gaa	gga	aca	atg	gat	act	gtc	768	
Ala	Ala	Glu	Gln	Lys	Ser	Lys	Asp	Leu	Glu	Gly	Thr	Met	Asp	Thr	Val		
				245					250					255			
aat	act	gtg	atg	atc	gcg	gtt	tct	gtt	gcc	att	aca	gtt	att	tct	att	816	
Asn	Thr	Val	Met	Ile	Ala	Val	Ser	Val	Ala	Ile	Thr	Val	Ile	Ser	Ile		
				260				265						270			
gtt	gct	gct	att	ttt	aca	tgc	gga	gct	gga	ctc	gct	gga	ctc	gct	gcg	864	
Val	Ala	Ala	Ile	Phe	Thr	Cys	Gly	Ala	Gly	Leu	Ala	Gly	Leu	Ala	Ala		
			275				280					285					
gga	gct	gct	gta	ggc	gca	gcg	gca	gct	gga	ggc	gca	gca	gga	gct	gct	912	
Gly	Ala	Ala	Val	Gly	Ala	Ala	Ala	Ala	Gly	Gly	Ala	Ala	Gly	Ala	Ala		
			290			295					300						
gcc	gca	acc	acg	gta	gca	aca	caa	att	aca	gtt	caa	gct	gtt	gtc	caa	960	
Ala	Ala	Thr	Thr	Val	Ala	Thr	Gln	Ile	Thr	Val	Gln	Ala	Val	Val	Gln		

- 3 -

305	310	315	320	
gcg gtg aaa caa gct gtt atc aca gct gtc aga caa gcg atc acc gcg				1008
Ala Val Lys Gln Ala Val Ile Thr Ala Val Arg Gln Ala Ile Thr Ala				
	325	330	335	
gct ata aaa gcg gct gtc aaa tct gga ata aaa gca ttt atc aaa act				1056
Ala Ile Lys Ala Ala Val Lys Ser Gly Ile Lys Ala Phe Ile Lys Thr				
	340	345	350	
tta gtc aaa gcg att gcc aaa gcc att tct aaa gga atc tct aag gtt				1104
Leu Val Lys Ala Ile Ala Lys Ala Ile Ser Lys Gly Ile Ser Lys Val				
	355	360	365	
ttc gct aag gga act caa atg att gcg aag aac ttc ccc aag ctc tcg				1152
Phe Ala Lys Gly Thr Gln Met Ile Ala Lys Asn Phe Pro Lys Leu Ser				
	370	375	380	
aaa gtc atc tcg tct ctt acc agt aaa tgg gtc acg gtt ggg gtt ggg				1200
Lys Val Ile Ser Ser Leu Thr Ser Lys Trp Val Thr Val Gly Val Gly				
	385	390	400	
gtt gta gtt gcg gcg cct gct ctc ggt aaa ggg att atg caa atg cag				1248
Val Val Val Ala Ala Pro Ala Leu Gly Lys Gly Ile Met Gln Met Gln				
	405	410	415	
ctc tcg gag atg caa caa aac gtc gct caa ttt cag aaa gaa gtc gga				1296
Leu Ser Glu Met Gln Gln Asn Val Ala Gln Phe Gln Lys Glu Val Gly				
	420	425	430	
aaa ctg cag gct gcg gct gat atg att tct atg ttc act caa ttt tgg				1344
Lys Leu Gln Ala Ala Ala Asp Met Ile Ser Met Phe Thr Gln Phe Trp				
	435	440	445	
caa cag gca agt aaa att gcc tca aaa caa aca ggc gag tct aat gaa				1392
Gln Gln Ala Ser Lys Ile Ala Ser Lys Gln Thr Gly Glu Ser Asn Glu				
	450	455	460	
atg act caa aaa gct acc aag ctg ggc gct caa atc ctt aaa gcg tat				1440
Met Thr Gln Lys Ala Thr Lys Leu Gly Ala Gln Ile Leu Lys Ala Tyr				
	465	470	475	480
gcc gca atc agc gga gcc atc gct ggc gca cat aaa acc aat aat ttt				1488
Ala Ala Ile Ser Gly Ala Ile Ala Gly Ala His Lys Thr Asn Asn Phe				
	485	490	495	
taa				1491

&lt;210&gt; 2

&lt;211&gt; 496

&lt;212&gt; PRT

- 4 -

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 2

Asp	Thr	Asn	Met	Ser	Ile	Ser	Ser	Ser	Ser	Gly	Pro	Asp	Asn	Gln	Lys
1				5					10					15	
Asn	Ile	Met	Ser	Gln	Val	Leu	Thr	Ser	Thr	Pro	Gln	Gly	Val	Pro	Gln
		20						25					30		
Gln	Asp	Lys	Leu	Ser	Gly	Asn	Glu	Thr	Lys	Gln	Ile	Gln	Gln	Thr	Arg
	35					40					45				
Gln	Gly	Lys	Asn	Thr	Glu	Met	Glu	Ser	Asp	Ala	Thr	Ile	Ala	Gly	Ala
	50				55				60						
Ser	Gly	Lys	Asp	Lys	Thr	Ser	Ser	Thr	Thr	Lys	Thr	Glu	Thr	Ala	Pro
65				70					75					80	
Gln	Gln	Gly	Val	Ala	Ala	Gly	Lys	Glu	Ser	Ser	Glu	Ser	Gln	Lys	Ala
			85				90						95		
Gly	Ala	Asp	Thr	Gly	Val	Ser	Gly	Ala	Ala	Ala	Thr	Thr	Ala	Ser	Asn
	100						105						110		
Thr	Ala	Thr	Lys	Ile	Ala	Met	Gln	Thr	Ser	Ile	Glu	Glu	Ala	Ser	Lys
	115						120					125			
Ser	Met	Glu	Ser	Thr	Leu	Glu	Ser	Leu	Gln	Ser	Leu	Ser	Ala	Ala	Gln
130					135				140						
Met	Lys	Glu	Val	Glu	Ala	Val	Val	Val	Ala	Ala	Leu	Ser	Gly	Lys	Ser
145				150					155					160	
Ser	Gly	Ser	Ala	Lys	Leu	Glu	Thr	Pro	Glu	Leu	Pro	Lys	Pro	Gly	Val
			165				170						175		
Thr	Pro	Arg	Ser	Glu	Val	Ile	Glu	Ile	Gly	Leu	Ala	Leu	Ala	Lys	Ala
		180					185						190		
Ile	Gln	Thr	Leu	Gly	Glu	Ala	Thr	Lys	Ser	Ala	Leu	Ser	Asn	Tyr	Ala
	195						200					205			
Ser	Thr	Gln	Ala	Gln	Ala	Asp	Gln	Thr	Asn	Lys	Leu	Gly	Leu	Glu	Lys
210					215						220				
Gln	Ala	Ile	Lys	Ile	Asp	Lys	Glu	Arg	Glu	Glu	Tyr	Gln	Glu	Met	Lys
225				230					235					240	
Ala	Ala	Glu	Gln	Lys	Ser	Lys	Asp	Leu	Glu	Gly	Thr	Met	Asp	Thr	Val
			245				250						255		
Asn	Thr	Val	Met	Ile	Ala	Val	Ser	Val	Ala	Ile	Thr	Val	Ile	Ser	Ile
		260					265						270		
Val	Ala	Ala	Ile	Phe	Thr	Cys	Gly	Ala	Gly	Leu	Ala	Gly	Leu	Ala	Ala
	275						280					285			
Gly	Ala	Ala	Val	Gly	Ala	Ala	Ala	Ala	Gly	Gly	Ala	Ala	Gly	Ala	Ala
290					295						300				
Ala	Ala	Thr	Thr	Val	Ala	Thr	Gln	Ile	Thr	Val	Gln	Ala	Val	Val	Gln
305				310					315					320	
Ala	Val	Lys	Gln	Ala	Val	Ile	Thr	Ala	Val	Arg	Gln	Ala	Ile	Thr	Ala
			325				330						335		
Ala	Ile	Lys	Ala	Ala	Val	Lys	Ser	Gly	Ile	Lys	Ala	Phe	Ile	Lys	Thr
	340						345					350			
Leu	Val	Lys	Ala	Ile	Ala	Lys	Ala	Ile	Ser	Lys	Gly	Ile	Ser	Lys	Val
	355					360					365				
Phe	Ala	Lys	Gly	Thr	Gln	Met	Ile	Ala	Lys	Asn	Phe	Pro	Lys	Leu	Ser
370					375					380					
Lys	Val	Ile	Ser	Ser	Leu	Thr	Ser	Lys	Trp	Val	Thr	Val	Gly	Val	Gly
385					390				395						400

- 5 -

```

Val Val Val Ala Ala Pro Ala Leu Gly Lys Gly Ile Met Gln Met Gln
              405              410              415
Leu Ser Glu Met Gln Gln Asn Val Ala Gln Phe Gln Lys Glu Val Gly
              420              425              430
Lys Leu Gln Ala Ala Ala Asp Met Ile Ser Met Phe Thr Gln Phe Trp
              435              440              445
Gln Gln Ala Ser Lys Ile Ala Ser Lys Gln Thr Gly Glu Ser Asn Glu
              450              455              460
Met Thr Gln Lys Ala Thr Lys Leu Gly Ala Gln Ile Leu Lys Ala Tyr
465              470              475              480
Ala Ala Ile Ser Gly Ala Ile Ala Gly Ala His Lys Thr Asn Asn Phe
              485              490              495

```

&lt;210&gt; 3

&lt;211&gt; 302

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Codon  
 optimised N-terminal section of Chlamydia  
 pneumoniae protein

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (1)..(30)

&lt;223&gt; S-tag and thrombin cleavage site

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (292)..(302)

&lt;223&gt; Histidine tag

&lt;400&gt; 3

```

Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser
  1              5              10              15
Pro Asp Leu Gly Thr Leu Val Pro Arg Gly Ser Ala Ile Ser Asp Pro
              20              25              30
Asp Thr Asn Met Ser Ile Ser Ser Ser Gly Pro Asp Asn Gln Lys
              35              40              45
Asn Ile Met Ser Gln Val Leu Thr Ser Thr Pro Gln Gly Val Pro Gln
              50              55              60
Gln Asp Lys Leu Ser Gly Asn Glu Thr Lys Gln Ile Gln Gln Thr Arg
              65              70              75              80
Gln Gly Lys Asn Thr Glu Met Glu Ser Asp Ala Thr Ile Ala Gly Ala
              85              90              95

```

- 6 -

Ser Gly Lys Asp Lys Thr Ser Ser Thr Thr Lys Thr Glu Thr Ala Pro  
                   100                                  105                                  110  
 Gln Gln Gly Val Ala Ala Gly Lys Glu Ser Ser Glu Ser Gln Lys Ala  
                   115                                  120                                  125  
 Gly Ala Asp Thr Gly Val Ser Gly Ala Ala Ala Thr Thr Ala Ser Asn  
                   130                                  135                                  140  
 Thr Ala Thr Lys Ile Ala Met Gln Thr Ser Ile Glu Glu Ala Ser Lys  
                   145                                  150                                  155                                  160  
 Ser Met Glu Ser Thr Leu Glu Ser Leu Gln Ser Leu Ser Ala Ala Gln  
                                   165                                  170                                  175  
 Met Lys Glu Val Glu Ala Val Val Val Ala Ala Leu Ser Gly Lys Ser  
                                   180                                  185                                  190  
 Ser Gly Ser Ala Lys Leu Glu Thr Pro Glu Leu Pro Lys Pro Gly Val  
                   195                                  200                                  205  
 Thr Pro Arg Ser Glu Val Ile Glu Ile Gly Leu Ala Leu Ala Lys Ala  
                   210                                  215                                  220  
 Ile Gln Thr Leu Gly Glu Ala Thr Lys Ser Ala Leu Ser Asn Tyr Ala  
                   225                                  230                                  235                                  240  
 Ser Thr Gln Ala Gln Ala Asp Gln Thr Asn Lys Leu Gly Leu Glu Lys  
                                   245                                  250                                  255  
 Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr Gln Glu Met Lys  
                                   260                                  265                                  270  
 Ala Ala Glu Gln Lys Ser Lys Asp Leu Glu Gly Thr Met Asp Thr Val  
                   275                                  280                                  285  
 Asn Thr Val Ala Ala Ala Leu Glu His His His His His His  
                   290                                  295                                  300

&lt;210&gt; 4

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 4

Ser Ala Lys Leu Glu Thr Pro Glu Leu  
   1                                  5

&lt;210&gt; 5

&lt;211&gt; 7

&lt;212&gt; PRT



- 7 -

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 5

Pro Lys Pro Gly Val Thr Pro

1 5

&lt;210&gt; 6

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 6

Gly Val Thr Pro Arg Ser Glu Val Ile

1 5

&lt;210&gt; 7

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 7

Glu Val Ile Glu Ile Gly

1 5

&lt;210&gt; 8

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 8

Ala Ile Lys Ile Asp Lys Glu Arg

1 5

&lt;210&gt; 9

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 9

Ser Gly Pro Asp Asn Gln

1 5

&lt;210&gt; 10

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 10

- 8 -

Ser Gly Asn Glu Thr Lys Gln Ile Gln  
1 5

&lt;210&gt; 11

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 11

Ser Glu Gly Gln Lys Ala Gly Ala Asp  
1 5

&lt;210&gt; 12

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 12

Thr Ala Ile Glu Glu Ala Ser Lys Ser  
1 5

&lt;210&gt; 13

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 13

Ser Lys Ser Met Glu Ser Thr Leu Glu  
1 5

&lt;210&gt; 14

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 14

Glu Tyr Gln Glu Met Lys Ala Ala Glu  
1 5

&lt;210&gt; 15

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 15

Glu Lys Gln Ala Ile Lys Ile Asp Lys Glu Arg Glu Glu Tyr  
1 5 10

- 9 -

&lt;210&gt; 16

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Chlamydia pneumoniae

&lt;400&gt; 16

Glu Thr Pro Glu Leu Pro Lys Pro Gly Val Thr Pro Arg Ser  
1 5 10